首页 工具
登录
购物车
Ixekizumab

Ixekizumab

产品编号 T38105   CAS 1143503-69-8
别名: LY2439821

Ixekizumab (LY2439821) 是一种人源化 IgG4 单克隆抗体,可选择性结合和中和白细胞介素 IL-17A ,Kd 值<3 pM。Ixekizumab 科阻断 IL-17A 与 IL-17RA 的结合,但不与其他 IL-17 家族成员结合。Ixekizumab 用于治疗中重度斑块型银屑病、银屑病关节炎和牛皮癣。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Ixekizumab Chemical Structure
Ixekizumab, CAS 1143503-69-8
规格 价格/CNY 货期 数量
1 mg ¥ 1,180 现货
5 mg ¥ 3,950 现货
10 mg ¥ 5,630 现货
25 mg ¥ 8,650 现货
50 mg ¥ 11,600 现货
产品目录号及名称: Ixekizumab (T38105)
点击图片重新获取验证码
选择批次  
纯度: 99.30%
纯度: 95.00%
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM.Ixekizumab blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members.Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis and psoriasis. arthritis, and psoriasis.
体外活性 Ixekizumab (0.1-10000 pM) dose-dependently inhibits the secretion of growth-regulated oncogene (GRO)α induced by human IL-17A or human IL-17A/F heterodimers from HT-29 cells. Similarly, Ixekizumab demonstrates dose-dependent inhibition of GROα secretion from HT-29 cells induced by cynomolgus monkey IL-17A.[1]
The equilibrium KD values of Ixekizumab for IL-17A in humans and cynomolgus monkeys were 1.8 pM and 0.8 pM, respectively. Ixekizumab exhibited binding to rabbit IL-17A as well, although with a lower affinity and heterogeneous binding (with KD values of 1.3 nM and 14 nM, respectively). Notably, Ixekizumab did not demonstrate any binding to IL-17A in either mice or rats.[1]
体内活性 Ixekizumab (0.001-1 mg/kg; i.v.; C57BL/6 mice) exhibits a dose-dependent reduction in the secretion of keratinocyte chemoattractant (KC) induced by human IL-17A in the plasma of C57BL/6 mice.
In male cynomolgus monkeys, upon intravenous (IV) administration of 1 mg/kg, Ixekizumab exhibits a mean half-life of 6.5 days for elimination. Subcutaneous (SC) administration of 1 mg/kg leads to an average maximum plasma concentration of approximately 11.1 µg/mL around 72 hours after dosing. The mean elimination half-life following the SC injection was approximately 10.3 days.[1]
别名 LY2439821
分子量 N/A
分子式 N/A
CAS No. 1143503-69-8

存储

store at low temperature | store at -20 ℃

计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

参考文献

1. Liu L, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39-50. 2. Griffiths CE, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551.
Kansuinine B Enokizumab Sarilumab (anti-IL-6Rα) Braylin 3,5-Dicaffeoyl-epi-quinic acid Carpinontriol B A-802715 Sarilumab

剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Ixekizumab 1143503-69-8 Immunology/Inflammation IL Receptor Interleukin LY 2439821 LY-2439821 LY2439821 Inhibitor inhibitor inhibit

 

陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼